Literature DB >> 27270653

Association of FCGR2A rs1801274 polymorphism with susceptibility to autoimmune diseases: A meta-analysis.

Chang'e Zhang1, Wenju Wang2, Hong'e Zhang3, Lulu Wei4, Shuping Guo4.   

Abstract

OBJECTIVES: The aim of this meta-analysis was to estimate the association between the FCGR2A rs1801274 polymorphism and the susceptibility to autoimmune diseases more precisely.
METHODS: A meta-analysis was conducted on the association between the FCGR2A gene variants and ADs by allelic contrast, homozygote contrast, the recessive model, and the dominant model.
RESULTS: A total of 17 studies with 30 comparisons in different populations and genotype-methods were available for this meta-analysis, including 10 Kawasaki disease (KD), 7 Ulcerative colitis (UC), 6 Crohn's disease (CD), 3 Rheumatoid arthritis (RA), 2 Systemic lupus erythematosus (SLE), 1 Autoimmune thyroid disease (ATD) and 1 diabetes mellitus type 1 (T1D). A significant association between FCGR2A rs1801274 polymorphism were found in KD (OR = 1.409, P < 0.001) and UC (OR = 1.237, P < 0.001). A overall meta-analysis increased risk of AD significant association between FCGR2A rs1801274 gene polymorphism and ADs under allelic (OR = 1.378, P=0.000), homozygous (OR: 1.866, P=0.001), dominant (OR = 1.667, P = 0.000) and recessive (OR = 1.434, P=0.000) in Asian population. Meanwhile, a decreased risk of AD was detected in the allelic (OR= 0.882, P = 0.011), homozygous (OR = 0.777, P = 0.013), dominant (OR = 0.850, P = 0.032) and recessive (OR = 0.840, P = 0.048) in African-American population.
CONCLUSIONS: This meta-analysis demonstrates that the FCGR2A rs1801274 G-allele confers susceptibility to KD and UC. Data also suggests that the FCGR2A rs1801274 polymorphism may be associated with the susceptibility of multiple ADs in Asian and African-American populations.

Entities:  

Keywords:  FCGR2A; Immune response; Immunity; Immunology and Microbiology Section; autoimmune diseases; meta-analysis; polymorphism; susceptibility

Mesh:

Substances:

Year:  2016        PMID: 27270653      PMCID: PMC5129943          DOI: 10.18632/oncotarget.9831

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Autoimmune diseases (ADs) are some complex disorders includes a substantial portion of pathobiology, the potential inheritance and induced environment, efficacy of the common therapies and co-occurrence among diseases. ADs accounted for 4-5% of the population and had always become difficult issues [1]. More recently, genome-wide association study (GWAS) and the sequencing approaches had been widely used to discover low-frequency disease risk alleles, and thousands susceptibility locis might predispose to multiple ADs. An expected observation for risk variants are shared across diseases. Colocalized genetic effects had enlighted a common pathway to interfere with pathobiology underlying defect immune functions [2, 3]. Several genes are associated in multiple ADs and are included in the shared network [3, 4]. The studied variant rs1801274 in FCGR2A had been reported and it was associated with the susceptibility to multiple autoimmune diseases, including systemic lupus erythematosus (SLE), Kawasaki disease (KD), diabetes mellitus type 1 (T1D), autoimmune thyroid disease (ATD), ulcerative colitis (UC), Crohn's disease (CD), rheumatoid arthritis (RA) [5-11], etc. However, the inadequate statistical data, ethnic differences or publication bias resulting in the controversial and inconclusive in different case-control studies. Here, we performed a meta-analysis to evaluate between FCGR2A rs1801274 polymorphisms and the susceptibility to multiple ADs.

RESULTS

Studies included in the meta-analysis

A total of 43 relevant studies with the FCGR2A rs1801274 polymorphism and autoimmune diseases were identified through PubMed and Web of Science search, and 17 articles included KD [6, 16–21], UC [9, 10, 22, 23], CD [7, 10, 22, 24], ATD [8], RA [7, 25], T1D [7] and SLE [26, 27] met the inclusion criteria for analysis. And 8 articles included multiple case-control studies in different autoimmune diseases or different populations. Overall, 30 eligible case-control comparisons including 16760 ADs and 30585 controls were enrolled in the meta-analysis. The ethnicities encompassed in qualified studies were stratified into Caucasian, non-Caucasian European, African-American, and Asian populations. The characteristics of the selected studies were summarized in (Supplementary Table S1) The results revealed significant association between FCGR2A rs1801274 A-allele and KD (OR = 1.409, 95% CI: 1.320-1.505, P < 0.001) and UC (OR = 1.237, 95% CI: 0.968-1.581, P < 0.001). In KD, significant association were observed in the population of Caucasian (OR = 1.466, 95% CI: 1.276-1.685, P < 0.001) and Asia population(OR = 1.395, 95% CI: 1.285-1.515, P < 0.001). For UC, significant association was found in Asia population (OR = 1.480, 95% CI: 1.356-1.615, P < 0.001) (Table 1).
Table 1

Meta-analysis of the FCGR2A rs1801274 polymorphism in autoimmune diseases

DiseasesComparisonPopulationSample sizeStudy numberTest of association (A vs G)ModelTest of heterogeneity
OR (95% CI)ZP ValueQP ValueI2 (%)
KDA vs GOverall17865101.409(1.320-1.505)10.23<0.001R9.530.395.6
Caucasian675421.466(1.276-1.685)5.39<0.001R0.100.7510
Asian1111181.395(1.285-1.515)7.93<0.001R9.050.24922.6
UCA vs GOverall975271.237(0.968-1.581)3.50<0.001R34.91082.8
Caucasian323851.059(0.959-1.169)1.130.257NA0NANA
Asian565511.480(1.356-1.615)8.80<0.001F2.800.5920
Non-Caucasian Europe85910.969(0.801-1.171)0.330.742NA0NANA
CDA vs GOverall813660.832(0.592-1.168)1.060.288R119.99095.8
Caucasian557830.709(0.363-1.382)1.010.312R115.24098.3
Non-Caucasian Europe132420.937(0.804-1.093)0.830.407F0.100.7470
Asian123411.043(0.867-1.253)0.440.657NA0.00NANA
RAA vs GOverall227831.008(0.493-2.061)0.020.983R50.43096.0
Caucasian185620.875(0.340-2.252)0.280.782R37.42097.3
Asian42211.358(0.965-1.909)1.760.079NA0NANA
SLEA vs GOverall436620.941(0.864-1.025)1.390.165R7.530.0686.7
AA vs GGOverall436620.886(0.743-1.057)1.340.179R8.280.00487.9
AA + AG vs GGOverall436620.914(0.797-1.049)1.280.200R6.550.0184.7
AG + GG vs AAOverall436621.072(0.932-1.234)0.970.330R4.220.0476.3

KD, Kawasaki disease; UC, Ulcerative colitis; CD, Crohn's disease; RA, rheumatoid arthritis; SLE, Systemic lupus erythematosus; HWE, Hardy–Weinberg equilibrium; OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model; NA, not applicable.

KD, Kawasaki disease; UC, Ulcerative colitis; CD, Crohn's disease; RA, rheumatoid arthritis; SLE, Systemic lupus erythematosus; HWE, Hardy–Weinberg equilibrium; OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model; NA, not applicable. The summary of meta-analysis for the FCGR2A rs1801274 polymorphism with autoimmune diseases was shown in Table 2. The results were showed no significant association between FCGR2A rs1801274 with susceptibility to these all phenotypes in overall populations. Additionally, sub-group analysis were also performed in the study. In Asian population, increased risk of ADs in the allelic (OR = 1.378, 95% CI: 1.287-1.475, P = 0.000), homozygous (OR = 1.866, 95% CI: 1.631-2.135, P = 0.001), dominant (OR = 1.667, 95% CI: 1.462-1.901, P = 0.000) and recessive (OR = 1.434, 95% CI: 1.319-1.559, P = 0.000) were found. In African-American population, decreased risk of AD was detected in the allelic (OR = 0.882, 95% CI: 0.800-0.972, P = 0.011), homozygous (OR = 0.777, 95% CI: 0.638-0.947, P = 0.013), dominant (OR = 0.850, 95% CI: 0.733-0.986, P = 0.032) and recessive (OR = 0.840, 95% CI: 0.707-0.999, P = 0.048). However, no significant association was found when all the contrasts were performed in Caucasian and non-Caucasian Europe populations.
Table 2

Meta-analysis of the association between the FCGR2A rs1801274 polymorphism and multiple autoimmune diseases

ComparisonPopulationNo. of studiesTest of association (A vs G)ModelTest of heterogeneityPublication bias
OR (95% CI)ZP ValueP ValueI2 (%)BeggEgger
A vs GOverall301.119(0.984-1.272)1.710.086R094.20.3630.148
Caucasian100.843(0.653-1.088)1.310.189R096.90.5920.542
Asian161.378(1.287-1.475)9.230R0.03443.30.4710.132
Non-Caucasian Europe30.949(0.843-1.070)0.850.395F0.916010.581
African-American10.882(0.800-0.972)2.530.011NANANANANA
AA vs GGOverall301.237(0.968-1.581)1.700.090R092.00.2320.068
Caucasian100.745(0.466-1.192)1.230.220R096.20.5920.579
Asian161.866(1.631-2.135)9.080F0.75100.3220.071
Non-Caucasian Europe30.901(0.71-1.145)0.850.396F0.917010.585
African-American10.777(0.638-0.947)2.500.013NANANANANA
AA + AG vs GGOverall301.186(0.998-1.409)1.940.052R087.10.1480.036
Caucasian100.839(0.613-1.148)1.100.272R093.80.8580.640
Asian161.667(1.462-1.901)7.640.000F0.9700.1260.118
Non-Caucasian Europe30.933(0.764-1.139)0.680.497F0.946010.602
African-American10.850(0.733-0.986)2.150.032NANANANANA
AG + GG vs AAOverall301.115(0.949-1.311)1.320.186R0.00092.60.5320.649
Caucasian100.780(0.552-1.102)1.410.159R0.00095.90.8580.535
Asian161.434(1.319-1.559)8.450.000R0.03243.70.5890.257
Non-Caucasian Europe30.933(0.7721.129)0.710.478F0.941010.563
African-American10.840(0.707-0.999)1.970.048NANANANANA

HWE, Hardy–Weinberg equilibrium; OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model; NA, not applicable.

HWE, Hardy–Weinberg equilibrium; OR, odds ratio; CI, confidence interval; F, fixed-effects model; R, random-effects model; NA, not applicable.

Test of heterogeneity

As shown in Table 1, the P value for the distribution of genotype for HWE in the control groups was calculated. Only one study in control population was not consistent with HWE. However, when studies were omitted individually from the meta-analysis to evaluate possible individual influences, heterogeneity disappear in CD and RA. Then we pooled results according to the ethnicity of study populations. Heterogeneity was found for the FCGR2A rs1801274 A-allele and CD in Caucasian population. The study with the highest OR were then excluded, and the heterogeneity disappeared but the result remained none significant (OR = 1.067, 95% CI: 0.995-1.143, P = 0.258).

Publication bias

Publication bias analysis on KD, UC, CD and overall phenotypes were performed. but not on RA, SLE, ATD and T1D due to small numbers of these studies. No obvious asymmetry evidence was detected according to the shapes of the funnel plots (data not shown). No evidence of publication bias by the method of Egger's test and Begg's tests (Table 2) were found. However, there was evidence of heterogeneity in this study. Assessment of potential sources of heterogeneity, by both stratified and meta-regression analyses, found that sample size, ethnicity, publication year or disease phenotype was unable to explain the variance. The results suggested that these potential factors were probably not the major sources of heterogeneity (data not shown).

DISCUSSION

ADs invokeed a wide spectrum of signs and symptoms, genetic analysis revealed multiple genes underlying distinct autoimmune conditions, which provided direct evidence that might have common immunopathologic mechanism. FCGR2A gene was located on chromosome 1q23, which consists of 7 exons spanning approximately 18.58 kb of genomic DNA. It encodes a member of a family of Fc γ receptors for immunoglobulin G. FCGR2A protein played an essential role in the protection against foreign antigens by removing antigen-antibody complexes in the circulation, and transduces activating signals into cells via immune receptor when ligated with immune complexes [28]. This stimulatory receptor was expressed by most leukocytes, including monocytes, dendritic cells, macrophages, natural killer cells, platelets and endothelial cells, and a subpopulation of T-cells. Upon binding of antibodies or autoantibodies, FCGR2A and FCGR3A activate immune cell functions, including phagocytosis, and the release of inflammatory mediators, were therefore linked to the pathogenic consequences which triggered by autoantibodies or immune complexes in multiple immune-mediated diseases [29].

Forest plot for the meta-analysis of association between FCGR2A rs1801274 polymorphism and kawasaki disease (KD) stratified by the ethnicity of study population

ORs and 95% CIs for the outcomes of the allelic comparison in the overall population ( < 0.001, OR = 1.41, 95% CI = 1.32-1.51) and Caucasians ( < 0.001, OR = 1.47, 95% CI = 1.28-1.69). The associated polymorphism FCGR2A rs1801274 was a missense variant leading to an amino-acid substitution of histidine by arginine at position 131 (H131R). The variant H131R was reported to interact differently with immunoglobulin G subclasses, and associated with the susceptibility to multiple autoimmune diseases. Specifically, the substitution of FCGR2A rs1801274 affected the Fc region of IgG receptor and determined the affinity of FCGR2A for IgG subclasses. This variant was capable of binding to and mediating phagocytosis with IgG2, potentially leading to altered immune response to infectious agents and activation of B cells and overproduction of cytokines [30]. However, owing to low prevalence or the inadequate statistical power, the discrepancy of the results was always achieved among different studies. Meta-analysis was a method of increasing the effective sample size through the pooling of datas from individual studies, thus enhancing the statistical power of the analysis for the estimation of genetic effect [31]. The results of the meta-analysis revealed significant association between the FCGR2A rs1801274 polymorphism and autoimmune diseases including KD and UC, indicating a protecting effect to KD and predisposing to UC, FCGR2A rs1801274 polymorphism might have no effect on CD or RA. However, the exact biological mechanism that the FCGR2A gene polymorphisms influence susceptibility to ADs remains unclear.

Forest plot for the meta-analysis of association between FCGR2A rs1801274 polymorphism and ulcerative colitis (UC)

ORs and 95% CIs for the outcomes of the allelic comparison in the overall population ( < 0.001, OR = 1.33, 95% CI = 1.13−1.55) and Asian ( < 0.001, OR = 1.48, 95% CI = 1.36−1.61). The significant association between FCGR2A rs1801274 polymorphism susceptibility to ADs in the overall population was failed to detect. Sub-population analysis revealed association between different genotypes and Asia population. The AD risk increased significantly in Asia populations using allelic, homozygous, recessive and dominant genetic models. Further studies including larger sample size, well-designed case-control studies in different ethnic populations will be needed to unravel their exact roles in the pathogenesis of multiple ADs. Several limitations of the present meta-analysis should be showed. First, for several autoimmune diseases, the number of studies is small, and this might cause insufficient power to detect slight association. Second, significant heterogeneity between-study was found in some comparisons. Third, the majority of the included studies were conducted in population of Caucasian and Asia, thus further studies in other ethnic populations were required. Fourth, the present meta-analysis was based on uncorrected estimates. A more precise analysis could be performed if the potential confounding factors including sex, age, environmental factors and other lifestyle factors were available. Thus, the results of the meta-analysis should be interpreted with caution.

Forest plot for the meta-analysis of association between FCGR2A rs1801274 polymorphism and autoimmune diseases stratified by the ethnicity

ORs and 95% CIs for the outcomes of the allelic comparison in the overall population ( = 0.086, OR = 1.12, 95% CI = 0.98-1.27) and Asian ( < 0.001, OR = 1.38, 95% CI = 1.29-1.48). In summary, the meta-analysis demonstrated that the FCGR2A rs1801274 polymorphism was associated with the susceptibility to multiple autoimmune diseases including KD and UC. It also provided evidence that the FCGR2A rs1801274 polymorphism may be associated with susceptibility to multiple ADs in Asia population. The FCGR2A rs1801274 polymorphism in multiple autoimmune diseases provides further evidence supporting the concept of common gene underlying multiple autoimmune diseases. Further studies including larger sample size, well-designed case-control studies in different ethnic populations will be needed to unravel their exact roles in the pathogenesis of multiple ADs.

MATERIALS AND METHODS

A comprehensive search examining the association between the FCGR2A rs1801274 polymorphism with autoimmune diseases were conducted. by searching the following Medical Subject Heading (MeSH) terms and/or text words: “Fc fragment of IgG, low-affinity IIa, receptor”, “FCGR2A”, “polymorphism”, “autoimmune diseases”, and “autoimmunity” in PubMed and Web of Science literature base for the period up to 2015-12-01, and relevant articles were identified for further literature filtering. A study was included if the following criteria were satisfied (1) case-control genetic association study published before June 2015; (2) genotype frequencies in the cases group and controls group were both available for estimating an odds ratios (OR) and their 95% confidence interval (CI). The exclusion criteria included: (1) studies that contained overlapping data with other literatures; (2) studies which the genotype or allele frequency could not be obtained; (3) data came from case-reports, reviews or abstracts; (4) control group did not confirm to Hardy-Weinberg equilibrium (HWE). The following information from each study were extracted: first author's name, publication year, country, ethnicity, genotype-methods, the number of cases and controls and allele frequencies of the FCGR2A rs1801274 polymorphism. Data extraction was performed independently by two authors, and disagreements were solved by discussion. Statistical analysis for the meta-analysis was conducted by Stata version 10.0 (Stata Corporation, College Station, TX). This meta-analysis examined the contrast of G versus A (allelic contrast), GG versus AA (homozygote contrast), G/G+G/A versus AA (dominant models), G/G versus A/A+G/A (recessive models). The heterogeneity between studies was evaluated by Cochrane's Q-statistic as well as I2-statistic which was used to quantify the effect of heterogeneity (I2 = 100% (Q-df)/Q) [12]. Subgroup analysis stratified by ethnicity were also performed in this meta-analysis. Meta-regression analysis was undertaken to explore potential sources of heterogeneity across studies when statistical heterogeneity was detected. The funnel plot was used to assess potential publication bias [13]. Egger's test and Begg's tests were performed to evaluate potential publication bias of the literatures [14, 15]. The significance of the intercept was calculated by the t-test suggested by Egger, P value less than 0.05 was considered significant publication bias.
  31 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease.

Authors:  Chiea Chuen Khor; Sonia Davila; Willemijn B Breunis; Yi-Ching Lee; Chisato Shimizu; Victoria J Wright; Rae S M Yeung; Dennis E K Tan; Kar Seng Sim; Jie Jin Wang; Tien Yin Wong; Junxiong Pang; Paul Mitchell; Rolando Cimaz; Nagib Dahdah; Yiu-Fai Cheung; Guo-Ying Huang; Wanling Yang; In-Sook Park; Jong-Keuk Lee; Jer-Yuarn Wu; Michael Levin; Jane C Burns; David Burgner; Taco W Kuijpers; Martin L Hibberd
Journal:  Nat Genet       Date:  2011-11-13       Impact factor: 38.330

3.  A genome-wide association study identifies three new risk loci for Kawasaki disease.

Authors:  Yoshihiro Onouchi; Kouichi Ozaki; Jane C Burns; Chisato Shimizu; Masaru Terai; Hiromichi Hamada; Takafumi Honda; Hiroyuki Suzuki; Tomohiro Suenaga; Takashi Takeuchi; Norishige Yoshikawa; Yoichi Suzuki; Kumi Yasukawa; Ryota Ebata; Kouji Higashi; Tsutomu Saji; Yasushi Kemmotsu; Shinichi Takatsuki; Kazunobu Ouchi; Fumio Kishi; Tetsushi Yoshikawa; Toshiro Nagai; Kunihiro Hamamoto; Yoshitake Sato; Akihito Honda; Hironobu Kobayashi; Junichi Sato; Shoichi Shibuta; Masakazu Miyawaki; Ko Oishi; Hironobu Yamaga; Noriyuki Aoyagi; Seiji Iwahashi; Ritsuko Miyashita; Yuji Murata; Kumiko Sasago; Atsushi Takahashi; Naoyuki Kamatani; Michiaki Kubo; Tatsuhiko Tsunoda; Akira Hata; Yusuke Nakamura; Toshihiro Tanaka
Journal:  Nat Genet       Date:  2012-03-25       Impact factor: 38.330

4.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

5.  Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study.

Authors:  Elena Sánchez; Mary E Comeau; Barry I Freedman; Jennifer A Kelly; Kenneth M Kaufman; Carl D Langefeld; Elizabeth E Brown; Graciela S Alarcón; Robert P Kimberly; Jeffrey C Edberg; Rosalind Ramsey-Goldman; Michelle Petri; John D Reveille; Luis M Vilá; Joan T Merrill; Betty P Tsao; Diane L Kamen; Gary S Gilkeson; Judith A James; Timothy J Vyse; Patrick M Gaffney; Chaim O Jacob; Timothy B Niewold; Bruce C Richardson; John B Harley; Marta E Alarcón-Riquelme; Amr H Sawalha
Journal:  Arthritis Rheum       Date:  2011-11

6.  Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations.

Authors:  Rinse K Weersma; J Bart A Crusius; Rebecca L Roberts; Bobby P C Koeleman; Rogelio Palomino-Morales; Simone Wolfkamp; Jade E Hollis-Moffatt; Eleonora A M Festen; Sander Meisneris; Roel Heijmans; Colin L Noble; Richard B Gearry; Murrary L Barclay; María Gómez-Garcia; Miguel A Lopez-Nevot; Antonio Nieto; Luis Rodrigo; Timothy R D J Radstake; Adriaan A van Bodegraven; Cisca Wijmenga; Tony R Merriman; Pieter C F Stokkers; A Salvador Peña; Javier Martín; Behrooz Z Alizadeh
Journal:  Inflamm Bowel Dis       Date:  2010-12       Impact factor: 5.325

7.  Genetic risk factors for infection in patients with early rheumatoid arthritis.

Authors:  L B Hughes; L A Criswell; T M Beasley; J C Edberg; R P Kimberly; L W Moreland; M F Seldin; S L Bridges
Journal:  Genes Immun       Date:  2004-12       Impact factor: 2.676

8.  Absence of association of FCGR2A gene polymorphism rs1801274 with Kawasaki disease in Greek patients.

Authors:  Anthoula Chatzikyriakidou; Louiza Aidinidou; Andreas Giannopoulos; Kyriaki Papadopoulou-Legbelou; Kallirhoe Kalinderi; Liana Fidani
Journal:  Cardiol Young       Date:  2014-04-28       Impact factor: 1.093

9.  [Single nucleotide polymorphism of FCGR2A gene in Han Chinese children with Kawasaki disease].

Authors:  Yu-Xiao Ji; Hong-Yan Zhang; Shu-Xiang Lin
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2013-03

10.  A genetic variant rs1801274 in FCGR2A as a potential risk marker for Kawasaki disease: a case-control study and meta-analysis.

Authors:  Jiayu Duan; Jiao Lou; Qing Zhang; Juntao Ke; Yanqi Qi; Na Shen; Beibei Zhu; Rong Zhong; Zhenling Wang; Lifeng Liu; Jing Wu; Wei Wang; Fangqi Gong; Xiaoping Miao
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

View more
  7 in total

1.  HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.

Authors:  Rebecca T Veenhuis; Zachary T Freeman; Jack Korleski; Laura K Cohen; Guido Massaccesi; Alessandra Tomasi; Austin W Boesch; Margaret E Ackerman; Joseph B Margolick; Joel N Blankson; Michael A Chattergoon; Andrea L Cox
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

2.  Searching for New Genetic Biomarkers of Axial Spondyloarthritis.

Authors:  Bartosz Bugaj; Joanna Wielińska; Katarzyna Bogunia-Kubik; Jerzy Świerkot
Journal:  J Clin Med       Date:  2022-05-20       Impact factor: 4.964

Review 3.  IL-23R mutation is associated with ulcerative colitis: A systemic review and meta-analysis.

Authors:  Ling-Long Peng; Ying Wang; Feng-Ling Zhu; Wang-Dong Xu; Xue-Lei Ji; Jing Ni
Journal:  Oncotarget       Date:  2017-01-17

4.  p27-V109G Polymorphism Is Not Associated with the Risk of Prostate Cancer: A Case-Control Study of Han Chinese Men in Central China.

Authors:  Meng Zhang; Qianjun Liang; Ligang Zhang; Zongyao Hao; Jun Zhou; Li Zhang; Song Fan; Chaozhao Liang
Journal:  Dis Markers       Date:  2018-03-20       Impact factor: 3.434

5.  FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.

Authors:  Pascale Paul; Pascal Pedini; Luc Lyonnet; Julie Di Cristofaro; Anderson Loundou; Mathieu Pelardy; Agnes Basire; Françoise Dignat-George; Jacques Chiaroni; Pascal Thomas; Martine Reynaud-Gaubert; Christophe Picard
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

6.  Association of Cytokine Gene Polymorphisms with Prostate Cancer Risk from a Study in Central China.

Authors:  Shun Xu; Yongtao Hu; Ligang Zhang; Shaoyu Yue; Li Zhang; Chaozhao Liang
Journal:  Contrast Media Mol Imaging       Date:  2022-08-13       Impact factor: 3.009

7.  FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity.

Authors:  Jonathan J Hubbard; Michal Pyzik; Timo Rath; Lisa K Kozicky; Kine M K Sand; Amit K Gandhi; Algirdas Grevys; Stian Foss; Susan C Menzies; Jonathan N Glickman; Edda Fiebiger; Derry C Roopenian; Inger Sandlie; Jan Terje Andersen; Laura M Sly; Kristi Baker; Richard S Blumberg
Journal:  J Exp Med       Date:  2020-10-05       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.